say Sedation Score (RSS) (41) interfere with the patient, because it is necessary to use acoustic and tactile stimulation. These manipulations themselves can cause undesired arousal and agitation, leading to patient discomfort and a possible increase in sedative and analgesic drug requirements. Under these circumstances, continuous and nonactivating methods like the noninvasive bispectral index (BIS) appear to be favorable over conventional sedation monitoring. BIS is a new processed electroencephalographic variable that monitors anesthetic and sedative levels on a relative scale, during the administration of different drugs (42) (43) (44) . For various agents (e.g., propofol and midazolam), it was shown that BIS may correlate with dose-dependent levels of anesthesia (43, (45) (46) (47) and ICU sedation (48 -51) . In volunteers, sedation and changes in memory function correlated well with the BIS (52) .
Recent studies imply that BIS also provides a measure of the anesthetic and sedative levels produced by ␣ 2 -agonists on a relative scale in volunteers/patients (53, 54) . Our study is the first, to the best of our knowledge, that used BIS to monitor the level of sedation with dexmedetomidine in mechanically ventilated ICU patients after surgery.
The objective of this study was to evaluate the safety and efficacy of dexmedetomidine in patients requiring mechanical ventilation after surgery. BIS was used to guide and monitor sedation levels.
MATERIALS AND METHODS
Patients. After we gained approval of the local ethics committees (Benjamin Franklin Medical Center, Free University of Berlin; Charité Medical Center, Campus Mitte, Humboldt-University of Berlin) and informed consent was given preoperatively, 30 patients were entered into this prospective, randomized, double-blind, placebo-controlled, bicenter phase II study. Inclusion criteria were that the patient required sedation and mechanical ventilation for Ն6 hrs after surgery. Exclusion criteria of the study were age Ͻ18 yrs, pregnancy, excessive obesity (body weight Ͼ50% above ideal body weight for height), unstable or uncontrolled diabetes, severe hepatic failure, excessive bleeding, serious trauma of the central nervous system, possibly active cerebral vasospasm or intracranial surgery, significant arrhythmias or high degree atrioventricular nodal block, and current or recent (within last 30 days) treatment with as well as contraindications for ␣ 2 -agonists and ␣ 2antagonists. Two patients in the placebo group were not included in the efficacy analysis be-cause of protocol deviation occurring during the study. One patient underwent repeated surgery because of postoperative bleeding. In the other patient, sedation could not be guided by BIS because of technical problems (cable breakage).
Materials and Supplies. The investigational drug was either dexmedetomidine HCl (100 g/mL) concentrate or placebo (0.9% saline). The study drug was provided in 2-mL ampoules, and the sterile solution was clear and colorless. The investigational drug was diluted in 48 mL of 0.9% saline and administered by using syringe pumps (Perfusor fm, B. Braun AG, Melsungen, Germany, and Pilot A or C, Becton Dickinson, Franklin Lakes, NJ).
BIS data were recorded during the study drug infusion period by using the electroencephalographic monitor ASPECT A-1000 (software version 3.12, two-channel referential lead; Aspect Medical Systems, Natick, MA).
Interventions. Screening procedures included a complete medical history and physical examination (height, weight, vital signs) and a 12-lead electrocardiogram. On the patient's arrival in the ICU, baseline measurements were completed including vital signs, 12-lead electrocardiogram, blood samples (blood gases, hematology, and blood chemistry), ventilation variables, Acute Physiology and Chronic Health Evaluation III score (55) , and Multiple Organ Dysfunction Score (56) .
Patients were instrumented with BIS leads (two-channel-referential measurement, frontotemporal application) on entry into the ICU. The electrode impedances were confirmed to be Ͻ10 k⍀ before study drug initiation. A 10-min resting period was allowed after instrumentation and before the baseline measurements. Two 30-sec averaged (bispectral smoothing) baseline BIS values were collected separated by an interval of Ն2 mins. After study drug initiation, BIS values were obtained every 10 mins during the first hour and then every 60 mins until discontinuation of the study drug infusion. Additional BIS values were documented if they were outside the targeted range as well as 10 mins after each intervention (i.e., adjustment of study drug infusion or supplemental propofol or morphine administration).
Study drug administration was initiated as soon as possible after arrival in the ICU but no later than 1 hr after admission to the ICU. All patients received a 10-min loading dose of 6.0 g·kg Ϫ1 ·hr Ϫ1 dexmedetomidine or placebo. The loading dose we chose in our study was the same as used in other multicenter phase II and III trials studying the efficacy and safety of dexmedetomidine. This was followed by a maintenance infusion of 0.4 g·kg Ϫ1 ·hr Ϫ1 . After the initial maintenance infusion, the rate was adjusted in increments of minimally 0.1 g·kg Ϫ1 ·hr Ϫ1 . The infusion dose range was kept between 0.1 and 0.7 g·kg Ϫ1 ·hr Ϫ1 as deemed clinically necessary to achieve and maintain a BIS between 60 and 70, indicating deep sleep. If the aimed BIS range could not be achieved or maintained by the study drug (dexmedetomidine or placebo) alone, the study drug was supplemented by propofol boli of 0.2 mg/kg or, after three successive boli, with an intravenous infusion of 0.5-4 mg·kg Ϫ1 ·hr Ϫ1 , as indicated, to achieve and maintain the desired BIS level. When weaning from ventilator and extubation was indicated, study drug infusion and, if necessary, propofol was adapted to reach a BIS range between 65 and 95. The patients were extubated when the BIS reached a level of 85 to 95 and they met the usual clinical criteria for extubation. After extubation, the infusion rate was adjusted to maintain a BIS score between 85 and 95. The maximal time of study drug infusion was limited to 72 hrs. If analgesia was required, morphine boli (2.0 mg), paracetamol, or both were administered. Additional sedative or analgesic medications during the study drug infusion period were limited to those mentioned previously, completed by pethidine (50-mg boli) in the case of shivering.
Weaning from ventilatory support was performed as quickly as possible. FIO 2 was decreased every 30 mins by 0.1 decrements if peripheral arterial oxygen saturation was Ͼ92% (goal, FIO 2 Յ0.4). Additional criteria were body temperature Ͼ36°C, hemodynamic stability, no shivering, and no bleeding requiring treatment. Extubation was performed if the patients met the following criteria: awake or arousable, neurologically intact, cooperative and comfortable, FIO 2 Յ0.4, positive endexpiratory pressure Ͻ5 cm H 2 O, pressure support Ͻ10 cm H 2 O, minute ventilation expired Ͼ4 and Ͻ15 L/min, tidal volume Ͼ5 mL/kg, and spontaneous respiratory rate Ͻ25/min.
Vital signs (heart rate, arterial blood pressure, respiratory rate, central venous pressure, and peripheral oxygen saturation) were monitored continuously and recorded every 10 mins during the first hour and every 60 mins from 1 hr after the start until the end of study drug infusion. After the end of the study, drug infusion vital signs were recorded every 3 hrs for 24 more hours (until the end of the study). Temperature was assessed every 6 hrs until the end of infusion and again at the end of the study. Acute Physiology and Chronic Health Evaluation III and MODS assessments were performed at baseline, at the end of drug infusion, and at the end of the study. In addition, a physical exam, a 12-lead electrocardiogram, and a complete set of laboratory evaluations including blood gases were repeated at the end of the study (approximately 24 hrs after the end of study drug infusion) to complete the study procedures.
Throughout the study, each patient was monitored for clinical or laboratory evidence of adverse events. An adverse event was defined as any undesirable medical occurrence in a patient. An adverse event could have been a symptom, sign, or abnormal laboratory finding or test result. Adverse event reports included date and time of onset, severity, duration, outcome, etiology, relationship to study drug (not related, probably not related, possible, or probable), any treatment required, and the action taken.
Statistics. In case of normal distribution (Kolmogorov-Smirnov), all data were expressed as mean Ϯ SEM; otherwise data were expressed as median and interquartile ranges. The total amount of propofol per hour (mg·kg Ϫ1 ·hr Ϫ1 ) was computed for each of the three time periods (while mechanically ventilated before weaning was started, during weaning, and after extubation) during study drug infusion. The Mann-Whitney rank sum test was used to compare the median doses of propofol (mg·kg Ϫ1 ·hr Ϫ1 ; before and during weaning, total consumption) and morphine (mg/hr and g·kg Ϫ1 ·hr Ϫ1 ; before and after extubation, total consumption) across groups for each of the two periods, respectively. The average BIS was calculated by using the area under the curve (AUC) divided by the length of study drug infusion period (AUC/T Ϫ 0). The trapezoidal rule was used to calculate AUC. The average BIS score was computed for each of the three time periods (while mechanically ventilated before weaning was started, during weaning, and after extubation), and the treatment groups were compared by using the Kolmogorov-Smirnov two-tailed test. Hemodynamic variables were compared with the Mann-Whitney test by using the area under the curve divided by the duration of the individual periods (AUC/time of period). Fisher's exact test was used to compare the need for additional pethidine, paracetamol, and catecholamines and to compare the frequency of adverse events between the groups. In case of single observations, p Ͻ .05 was considered statistically significant. In case of repeated observations (propofol and morphine consumption, hemodynamics), a correction according to Bonferroni was performed and p Ͻ .01 was considered statistically significant.
RESULTS
Basic patient characteristics assessed during the preoperative screening visits did not significantly differ between dexmedetomidine-treated and placebo patients, except for gender. There was also no significant preoperative difference concerning major preexisting diseases, alcohol-related medical history, and type of surgery (Table 1) .
Both groups were within the targeted BIS ranges ( Table 2) . During mechanical ventilation, before weaning was started, and during weaning, the dexmedetomidine-treated group required significantly less propofol than the group treated with placebo to achieve the same level of BISguided sedation ( Table 2 ). During weaning, additional propofol was given in six of 15 dexmedetomidine-treated patients and in 11 of 13 patients receiving pla-cebo. After extubation, only one patient of the placebo group needed propofol (total amount 0.13 mg/kg) because of mild restlessness.
During the entire study drug administration period, morphine requirements (mg/hr, median, interquartile range) for dexmedetomidine were reduced by 58% (0.28, 0.07-0.79; placebo, 0.68, 0.12-1.10; p ϭ .05). During mechanical ventilation, median morphine administered to the dexmedetomidine patients was one third of that given to the placebo group (Table 2) . Differences between treatment groups were not statistically significant;
however, this study was not powered to detect statistically valid differences in morphine use. Ten of 15 patients in the dexmedetomidine-treated group and 11 of 13 in the placebo group needed morphine during respiratory support, and 7 of 15 vs. 9 of 13, respectively, needed morphine after extubation for additional pain therapy. No patient in the dexmedetomidine group received paracetamol, either before or after extubation, whereas two patients in the placebo group received paracetamol for pain management (one before extubation and one after extubation; p ϭ .498). These patients re- Baseline measurements performed after admission to the ICU did not show significant differences between groups concerning vital signs, laboratory variables, and illness severity scores (Table  3) .
Heart rate ( Figure 1 ) was significantly higher in the placebo group after extubation (p Ͻ .01). Systolic arterial blood pressure was significantly higher (p Ͻ .0001) during weaning and after extubation (p ϭ .05) in the placebo group, and diastolic arterial blood pressure was significantly higher during weaning (p ϭ .01) and after extubation (p Ͻ .01) in the placebo group (Figure 1) . The number of patients receiving norepinephrine or dopamine to treat hypotension as an adverse event was not different between both groups (norepinephrine, four of 15; dopamine, six of 15 patients in each group). No significant differences were observed in hemodynamics between the two study groups either during loading period or during the maintenance period before weaning was started. Central venous pressure, respiratory rate, peripheral arterial oxygen saturation, and laboratory results did not differ between both groups.
Time to extubation did not differ between groups ( Table 2 ). The percentage of patients with a weaning duration Յ3 hrs was 67% (ten of 15) in each treatment group. The time from extubation to discontinuation of the study drug infusion was between 6 and 7 hrs for all patients. Differences between groups were not statistically significant (p ϭ .865).
Dexmedetomidine was generally safe and well tolerated. The mean dose of dexmedetomidine administered was 7.3 g/kg. The median total duration of infusion did not differ between groups (Table 2). In this study, 100% (15 of 15) of the dexmedetomidine-treated patients and 87% (13 of 15) of the placebo group experienced at least one adverse event, most of which were mild or moderate in severity ( Table 4 ). The proportion of patients with at least one adverse event that was considered to be related to study drug administration was 47% (seven of 15) and 40% (six of 13) in the dexmedetomidine and placebo groups (p Ͼ .999), respectively. Three patients in the dexmedetomidine and five patients in the placebo group experienced serious adverse events ( Table 5 ). None of these serious adverse events were deemed related to the study medication. One patient in the placebo group died of cardiac arrest of unknown origin 20 days after discontinuation of the study. There was no significant difference in the frequency of adverse and serious adverse events between placebo and dexmedetomidine-treated patients.
DISCUSSION
Dexmedetomidine was a well tolerated and safe first-line agent for BIS-guided sedation in our study. In contrast to other clinical studies, we used BIS to assess the level of sedation while using the ␣ 2 -adrenergic receptor agonist dexmedetomidine for care of postsurgical patients in the ICU. Weaning period and time to extubation were equal in both groups. This may be related to the fact that average BIS scores were in the desired range and did not significantly differ between the treatment groups, indicating equivalent levels of sedation. Therefore, BIS-guided sedation seems to be suitable also during administration of dexmedetomidine, similar to other sedation regimens in surgical ICU settings (48 -50) . At this point we do not want to omit potential limitations of BIS in general anesthesia settings, which were discussed recently (57) (58) (59) . These publications cited awareness under general anesthesia despite very low BIS numbers. In intensive care, our interest is not so much awareness but guiding sedation and avoiding inadequate levels of sedation to maximize the comfort of patients and caregivers. Additionally, we think that BIS in terms of a monitor of cortical electrical activity is one of the best currently available "objective" techniques to compare sedative drugs. There are limitations with that, too, because the BIS does not tell us anything about arousability, and its predictive value is not proven. In physiologic sleep, BIS levels Ͻ30 were detected (60) , and the volunteers were arousable. This is not the case if propofol and inhalative drugs like isoflurane or desflurane are used and these deep levels are achieved.
To the best of our knowledge, it is unclear if benzodiazepines show the same characteristics as propofol. One characteristic of dexmedetomidine seems to be its easy arousability without clinical signs of stress. Propofol requirements were decreased in the dexmedetomidine group, although all patients in both treatment groups required additional propofol to maintain a BIS of 60 -70 (deep sleep) during mechanical ventilation. Because the study safety protocol had set an upper infusion rate limit for dexmedetomidine, the additional propofol requirement may be related to this fact in the dexmedetomidine group. In other clinical studies (23, 24, 28, 61) involving approximately 1,100 patients and using the RSS for sedation monitoring, the requirement for additional sedative agents (propofol or midazolam) was significantly less in the dexmedetomidine-treated patients. Another reason for the different propofol requirements (between our study and those cited previously) might be that the level of sedation differed between BISand RSS-guided studies (23, 24, 28) . The BIS of 60 -70 cannot easily be interpreted in terms of RSS, because the RSS assess- ment measures reaction to tactile and acoustic stimuli. This may account for broad BIS ranges associated with each RSS level of sedation.
Many studies have described the analgesic potency of dexmedetomidine (19, 27, 28, 61) . In our study, the total amount of morphine per hour administered was Ͼ40% lower in dexmedetomidine-treated patients. Before extubation, morphine in the dexmedetomidine-group was reduced by 58%. In contrast to other studies comparing dexmedetomidine treatment to propofol-or midazolamand morphine-based postsurgical sedation and analgesia, these differences were not statistically significant. In the study by Bachand et al. (27) involving 401 patients, during study drug administration, the dexmedetomidine-treated patients required significantly less morphine than the placebo group (0.43 Ϯ 0.05 mg/hr vs. 0.88 Ϯ 0.07 mg/hr, respectively, p Ͻ .0001). In another multiple-site study, Herr (61) reported that the morphine requirements during intubation for 144 dexmedetomidine-treated patients vs. 145 propofol-treated patients were 0.16 Ϯ 0.04 mg/hr and 0.61 Ϯ 0.08 mg/hr (p ϭ .0003), respectively; during 6 hrs postextubation, requirements were 1.43 Ϯ 0.25 mg/hr and 6.24 Ϯ 1.16 mg/hr (p ϭ .0048), respectively. This means that in these studies, morphine consumption was higher in both groups than in our study. We cannot rule out that different sedation levels as maintained by the nondisruptive BIS monitoring system in our study compared with previous dexme-detomidine studies (27, 28, 61) may have masked the overall need for analgesics.
Dexmedetomidine improved hemodynamic stability particularly during weaning and after extubation. The placebo group showed a more intense hypertensive blood pressure response when patients were weaned from ventilatory support and an increase in heart rate and blood pressure after extubation. This is in accordance with previous studies reporting the beneficial effect of dexmedetomidine on hemodynamic stability after surgery (30, (35) (36) (37) (38) . Although our study did not show any differences in morbidity or mortality rates between the groups, we think it could be of major importance in critically ill patients to avoid stress during weaning and after successful extubation, when patients often suffer from stressful stimuli like endotracheal suctioning, physiotherapy, and mobilization. Stress is considered to be a major risk factor in myocardial ischemia after surgery (62) . About one fifth to one fourth of the patients receiving placebo were above 20% of the baseline level of heart rate and blood pressure during weaning and after extubation, which was avoided in the dexmedetomidine-treated patients. The purpose of our phase II clinical trial was to study the efficacy and safety of dexmedetomidine. At this moment, we cannot state that there is any benefit in terms of outcome and costs when dexmedetomidine is used. Therefore, larger studies are required.
Nearly all patients in our study experienced at least one adverse event. How-ever, the number of patients with probable, possible, or unclear related adverse events did not differ between treatment groups. Overall, the adverse events were typical of a postsurgical population and in accordance with previous clinical investigations on dexmedetomidine (25) . Serious adverse events observed were typical for patients after major surgery and with significant preexisting diseases. However, none of the serious adverse events in our study were deemed to be related to the study medication.
CONCLUSION
Dexmedetomidine was safe and efficacious when using sedation monitoring by BIS. The advantage of BIS over the RSS method is that the BIS method is continuous and nonintrusive. In agreement with previous studies (27, 28, 61) in which the RSS was used to assess the level of sedation, dexmedetomidine provided effective sedation, reduced requirements for additional analgesics, and improved hemodynamic stability. 
